EX-99.1
3
a09-14989_1ex99d1.htm
EX-99.1
Exhibit 99.1
1600 West Merit Parkway · South Jordan,
UT 84095
Telephone: 801-253-1600 · Fax:
801-253-1688
PRESS
RELEASE
FOR IMMEDIATE RELEASE
Date:
June 3,
2009
Contact:
Anne-Marie
Wright, Vice President of Corporate Communications
Phone:
(801) 208-4167 e-mail: awright@merit.com Fax:
(801) 253-1688
MERIT
MEDICAL ACQUIRES
EN SNARE® PRODUCT
RIGHTS FROM HATCH MEDICAL
SOUTH JORDAN, UTAH- Merit Medical Systems, Inc. (NASDAQ: MMSI), a
leading manufacturer and marketer of proprietary disposable medical devices
used in interventional and diagnostic procedures, particularly in cardiology,
radiology and gastroenterology, today announced that it has acquired
intellectual property, including patents, certain trademarks and know-how,
associated with the EN Snare® foreign body removal device from Hatch Medical,
L.L.C.
The EN Snare® device is used by physicians for retrieval and removal of
stents, vena cava filters and embolic coils as well as the manipulation of AAA
stent grafts and guidewire "pull-throughs".
A third party currently manufactures and distributes the EN Snare®
product line. Merit intends to
exclusively manufacture and distribute the products worldwide beginning early January 2010. Until then, Merit will receive royalties for
units sold by the third party.
Current worldwide sales of the EN Snare® product line are estimated at
approximately $6 million based on IMS data and management's estimate of
international sales. According to IMS
data, the average sales price for the EN Snare® is $330.00. Merit's management believes that its direct
sales force in both the United States and
Europe
will enhance the growth prospects going forward. Management also believes the acquisition will
be immediately accretive and estimates earnings of $0.06-0.08 cents after tax
in the first full year of production and sales.
The purchase price consists of an initial payment of $14 million with
an additional payment of $7 million due once Merit introduces the product into
the marketplace, which Merit believes will be early January 2010. The purchase price will be funded by
existing cash reserves and a partial use of Merit's $30 million credit
facility.
"We are pleased with this acquisition, which will serve as a foundation
for entry into the snare market", said Fred P. Lampropoulos, Merit's Chairman
and Chief Executive Officer. "Merit
intends to offer additional snare products for gastroenterology and cardiology
in the future. Overall, we believe the
combined market opportunities for snare products exceed $125 million. The products are sold at our current call
points and enhance our overall product offering".
CONFERENCE CALL
Merit invites all interested parties to participate in a conference
call today, (Wednesday, June 3, 2009) at 5:00 p.m. Eastern (4:00 p.m.
Central, 3:00 p.m. Mountain, and 2:00 p.m. Pacific). The telephone numbers to call are (domestic)
877-941-6012; and (international) 480-248-5081.
A live webcast will also be available for the conference call at www.merit.com
and www.fulldisclosure.com.
During the conference call, the information set forth in this release
will be discussed in more detail.
ABOUT
MERIT
Founded
in 1987, Merit Medical Systems, Inc. is engaged in the development,
manufacture and distribution of proprietary disposable medical devices used in
interventional and diagnostic procedures, particularly in cardiology, radiology
and gastroenterology. Merit serves
client hospitals worldwide with a domestic and international sales force totaling
approximately 100 individuals. Merit
employs approximately 1,800 people worldwide, with facilities in Salt Lake City
and South
Jordan, Utah; Angleton, Texas; Richmond,
Virginia; Maastricht and Venlo, The Netherlands; and Galway, Ireland.
Statements
contained in this release which are not purely historical, are forward-looking
statements within the meaning of the Private Securities Litigation Reform Act
of 1995 and are subject to risks and uncertainties such as those described in
Merit's Annual Report on Form 10-K for the year ended December 31,
2008. Such risks and uncertainties
include risks relating to: infringement of Merit's technology or the assertion
that Merit's technology infringes the rights of other parties; downturn of the
national economy and its affect on Merit's revenues, collections and supplier
relations; termination of supplier
relationships, or failure of suppliers to perform; product recalls and product
liability claims; delays in obtaining regulatory approvals, or the failure to
maintain such approvals; inability to successfully manage growth through
acquisitions; concentration of Merit's revenues among a few products and
procedures; development of new products and technology that could render Merit's
products obsolete; market acceptance of new products; introduction of products
in a timely fashion; price and product competition; availability of labor and
materials; cost increases; and fluctuations in and obsolescence of inventory;
volatility of the market price of Merit's common stock; foreign currency
fluctuations; changes in key personnel; work stoppage or transportation
risks; modification or limitation of governmental or private insurance
reimbursement; changes in health care markets related to health care reform
initiatives; impact of Merit's business by force majeure factors, including
severe weather conditions; failure to comply with applicable environmental laws
and other factors referred to in Merit's Annual Report on Form 10-K for
the year ended December 31, 2008, and other reports filed with the
Securities and Exchange Commission. All
subsequent forward-looking statements attributable to Merit or persons acting
on its behalf are expressly qualified in their entirety by these cautionary
statements. Actual results will differ, and may differ materially, from
anticipated results. Financial estimates
are subject to change and are not intended to be relied upon as predictions of
future operating results, and Merit assumes no obligation to update or disclose
revisions to those estimates.
# # #

EX - 99 . 1 3 a09 - 14989 _ 1ex99d1 . htm EX - 99 . 1 Exhibit 99 . 1 1600 West Merit Parkway · South Jordan , UT 84095 Telephone : 801 - 253 - 1600 · Fax : 801 - 253 - 1688 PRESS RELEASE FOR IMMEDIATE RELEASE Date : June 3 , 2009 Contact : Anne-Marie Wright , Vice President of Corporate Communications Phone : ( 801 ) 208 - 4167 e - mail : awright@merit.com Fax : ( 801 ) 253 - 1688 MERIT MEDICAL ACQUIRES EN SNARE ® PRODUCT RIGHTS FROM HATCH MEDICAL SOUTH JORDAN , UTAH - Merit Medical Systems , Inc . ( NASDAQ : MMSI ) , a leading manufacturer and marketer of proprietary disposable medical devices used in interventional and diagnostic procedures , particularly in cardiology , radiology and gastroenterology , today announced that it has acquired intellectual property , including patents , certain trademarks and know - how , associated with the EN Snare ® foreign body removal device from Hatch Medical , L . L . C . The EN Snare ® device is used by physicians for retrieval and removal of stents , vena cava filters and embolic coils as well as the manipulation of AAA stent grafts and guidewire " pull - throughs " . A third party currently manufactures and distributes the EN Snare ® product line . Merit intends to exclusively manufacture and distribute the products worldwide beginning early January 2010 . Until then , Merit will receive royalties for units sold by the third party . Current worldwide sales of the EN Snare ® product line are estimated at approximately $ 6 million based on IMS data and management 's estimate of international sales . According to IMS data , the average sales price for the EN Snare ® is $ 330.00 . Merit 's management believes that its direct sales force in both the United States and Europe will enhance the growth prospects going forward . Management also believes the acquisition will be immediately accretive and estimates earnings of $ 0.06 - 0.08 cents after tax in the first full year of production and sales . The purchase price consists of an initial payment of $ 14 million with an additional payment of $ 7 million due once Merit introduces the product into the marketplace , which Merit believes will be early January 2010 . The purchase price will be funded by existing cash reserves and a partial use of Merit 's $ 30 million credit facility . " We are pleased with this acquisition , which will serve as a foundation for entry into the snare market " , said Fred P . Lampropoulos , Merit 's Chairman and Chief Executive Officer . " Merit intends to offer additional snare products for gastroenterology and cardiology in the future . Overall , we believe the combined market opportunities for snare products exceed $ 125 million . The products are sold at our current call points and enhance our overall product offering " . CONFERENCE CALL Merit invites all interested parties to participate in a conference call today , ( Wednesday , June 3 , 2009 ) at 5 : 00 p.m. Eastern ( 4 : 00 p.m. Central , 3 : 00 p.m. Mountain , and 2 : 00 p.m. Pacific ) . The telephone numbers to call are ( domestic ) 877 - 941 - 6012 ; and ( international ) 480 - 248 - 5081 . A live webcast will also be available for the conference call at www.merit.com and www.fulldisclosure.com . During the conference call , the information set forth in this release will be discussed in more detail . ABOUT MERIT Founded in 1987 , Merit Medical Systems , Inc . is engaged in the development , manufacture and distribution of proprietary disposable medical devices used in interventional and diagnostic procedures , particularly in cardiology , radiology and gastroenterology . Merit serves client hospitals worldwide with a domestic and international sales force totaling approximately 100 individuals . Merit employs approximately 1,800 people worldwide , with facilities in Salt Lake City and South Jordan , Utah ; Angleton , Texas ; Richmond , Virginia ; Maastricht and Venlo , The Netherlands ; and Galway , Ireland . Statements contained in this release which are not purely historical , are forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties such as those described in Merit 's Annual Report on Form 10 - K for the year ended December 31 , 2008 . Such risks and uncertainties include risks relating to : infringement of Merit 's technology or the assertion that Merit 's technology infringes the rights of other parties ; downturn of the national economy and its affect on Merit 's revenues , collections and supplier relations ; termination of supplier relationships , or failure of suppliers to perform ; product recalls and product liability claims ; delays in obtaining regulatory approvals , or the failure to maintain such approvals ; inability to successfully manage growth through acquisitions ; concentration of Merit 's revenues among a few products and procedures ; development of new products and technology that could render Merit 's products obsolete ; market acceptance of new products ; introduction of products in a timely fashion ; price and product competition ; availability of labor and materials ; cost increases ; and fluctuations in and obsolescence of inventory ; volatility of the market price of Merit 's common stock ; foreign currency fluctuations ; changes in key personnel ; work stoppage or transportation risks ; modification or limitation of governmental or private insurance reimbursement ; changes in health care markets related to health care reform initiatives ; impact of Merit 's business by force majeure factors , including severe weather conditions ; failure to comply with applicable environmental laws and other factors referred to in Merit 's Annual Report on Form 10 - K for the year ended December 31 , 2008 , and other reports filed with the Securities and Exchange Commission . All subsequent forward - looking statements attributable to Merit or persons acting on its behalf are expressly qualified in their entirety by these cautionary statements . Actual results will differ , and may differ materially , from anticipated results . Financial estimates are subject to change and are not intended to be relied upon as predictions of future operating results , and Merit assumes no obligation to update or disclose revisions to those estimates . # # #